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Objective: This study assessed the performance of pulse oxi-
metry as a screening method for the detection of critical
congenital heart defects (CHD) in asymptomatic newborn
babies.
Background: Screening for critical congenital heart defects
in newborn babies can aid in early recognition, which may
lead to improved outcome. The potential predictive value of
using pulse oximetry to screen for significant cyanotic CHD in
newborns has been unclear. One difficulty of determining the
potential value of universal screening of newborns with pulse
oximetry from previous studies is that the relative infre-
quency of CHD made any individual study less able to
demonstrate benefit. This meta-analysis with 229,421
newborn babies makes this a more powerful study.
Methods: In this meta-analysis, the authors searched
Medline (1951e2011), Embase (1974e2011), Cochrane Library
(2011), and SciSearch (1974e2011) for studies that assessed the
accuracy of pulse oximetry for the detection of critical CHD in
asymptomatic newborn babies. Two reviewers selected
studies that met the predefined criteria for population, tests,
and outcomes, and sensitivity, specificity, and corresponding
95% CIs for individual studies were determined.
Results: Thismeta-analysis identified 13 studies, published
from 2001 to 2011, that screened 229,421 asymptomatic
newborn infants for critical CHD (defined as disorders from
which infants died or required invasive procedures or surgery
in the first 28 days of life). The overall sensitivity of pulse
oximetry for detection of critical CHD was 76.5%. The speci-
ficity was 99.9%, with a false-positive rate of 0.14%.
Measurementofpulseoximetrybefore24 hofage improved
sensitivity from 77.5% to 84.8% (a nonsignificant difference)
but increased the false-positive rate from 0.05% to 0.5% (a
significantdifference; p¼ .0017). Locationof thepulseoximeter
probe did not affect sensitivity or the frequency of false-
positive results. Thangaratinam and colleagues concluded
that pulse oximetry is a highly specific test for detection of
critical CHD in newborn infants, and that the false-positive
rate is low, especially when done after 24 h of age.
Conclusion: Pulse oximetry is highly specific and moder-
ately sensitive for detection of critical CHD and it meets the
criteria for universal screening.
Clinical perspective
Pulse oximetry screening can lead to the early detection of
lesions such as coarctation of the aorta, interrupted aortic
arch, transposition of the aorta, aortic and pulmonary
stenosis, tetralogy of Fallot, pulmonary atresia and total
anomalous pulmonary venous connection. Early correction of
these lesions before the onset of acidosis and decompensation
can lead to an improved outcome.
The American Academy of Pediatrics endorsed universal
newborn screening with pulse oximetry earlier this year and
stated that screening should be performed after 24 h of age
and should include readings from both the right hand andeither foot. They recommend a “pass” oxygen saturation level
of 95%, repeat screens at oxygen saturations of 90%e95%, and
immediate evaluation in infants whose pulse oximetry read-
ings are less than 90%.
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Summary of ROMICAT II study
The ROMICAT II study was a multi-centric study aimed to
evaluate the effectiveness of coronary computed tomographic
angiography (CCTA) in suspected patients of acute coronary
syndrome (ACS) seen in the emergency room (ER). Eligibility
criteria were patients with acute chest pain not showing
ischemic changes in the ECG and having normal troponin
levels. Out of a total 1000 acute chest patients enrolled, 501
were randomly assigned to the investigation group where
CCTA, performed as early as possible, was the first diagnostic
test. The remaining 499 patients were given standard emer-
gency room care. The following end points were compared in
the two groups, both at baseline and after 28 days: (i) duration
of hospitalization (ii) time to diagnosis (iii) direct discharge
rate from ER (iv) re-hospitalization after 28 days (v) adverse
cardiac events after 28 days.
A total 8% patients with acute chest pain had acute coro-
nary syndrome (mean age 54  8, male 53%) .When compared
to patients receiving standard evaluation, patients under-
going CCTA were observed to have shorter hospital stay
(reduced by 7.6 h, P < 0.001), duration of hospitalization
(23.2  37.0 h vs. 30.8  28.0 h, P < 0.001), and a higher inci-
dence of discharge done directly from the emergency room
(47% vs. 12%, P < 0.001). The incidence of adverse cardiac
events and re-hospitalization, and the cost of care ($4289 (Rs.
239540) vs. $ 4060 (Rs. 226751)), were found to be comparable
in the two groups.
Emergency use of CCTA in ACS patients, reduced the time
to diagnosis by quicker exclusion of CAD, leading to faster
discharge (done directly from ER) and lesser need for hospital
admission at the initial presentation (30% vs. 60%, P, 0.001).
The overall morbidity and readmission rates (at 1 month) and
cost of care were however not reduced. Significantly, in
patients in whom ACS was diagnosed, duration of hospitali-
zationwas similar in the two groups (86.3 72.3 vs. 83.8 61.3,
P ¼ 0.87).
Clinical perspective
The ROMICAT II study shows that in patients presenting with
acute chest pain, use of coronary computed tomography
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and also allowed for the direct discharge from the emergency
room. At the same time, there was no decrease in the overall
cost of care and increased radiation exposure.
Now putting these results in proper perspective, the
patients of ROMICAT II had an average age of 54 years, 47%
were women, all had normal ECG’s and all had normal
troponin levels. With all these parameters, the probability of
occurrence of coronary artery disease itself is so low that
whether one needs to do further testing at all in these patients
can be questioned and most definitely cannot be recom-
mended as a general policy for all. Most of us would probably
not ask for any investigations beyond a few hours of obser-
vation, some serial ECGs and a troponin level at the end of it
all!
If you want to consider this from country wise perspective
then for a country like the USA where even one missed
coronary event can lead to a lawsuit, protective medicine will
probably result in this study leading to CTA becoming part of
the emergency room protocols for chest pain. This type of
protective medicine fortunately is not yet practiced in India.
If we look at the cost of care of chest pain (excess of Rs 2
lakhs!), then perhaps a CTA within a few hours of admission
cutting down the cost of admission could be one new way of
looking at this issue but then this was not the question
addressed in this study.
At the same time one should not discount the utility of
coronary CT angiography in select situations in the emer-
gency room, where you want to be very confident about the
coronary anatomy (e.g. VIP or faculty colleague or relative) or
where a patient keeps coming back and will not be convinced
without a normal report, then a CTA is the answer.
So, in conclusion, in most situations especially as a public
policy, simple observation and clinical testing would be better
than CTA, though a CTA should always be available for
selected situations.
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“By failing to prepare you are preparing to fail.” e Benjamin
Franklin
Intra-aortic balloon counter-pulsation (IABP) is one of the
most commonly used haemodynamic support device in the
setting of haemodynamic instability complicating myocardialinfarction. IABP support gets class I recommendation for this
condition even though the evidence for such recommenda-
tion is scarce. In the IABP SHOCK II trial 600 patients with
acute myocardial infarction and cardiogenic shock under-
going early revascularization were randomised to IABP and no
IABP. IABP use was not associated with any significant
difference in the 30-day mortality or hospital stay. At 30 days,
39.7% of the IABP patients and 41.3% of controls had died
( p ¼ 0.69). Interestingly, there was no IABP related side effects
in the IABP group. Most of the patients (86.6%) received IABP
immediately after the procedure and 10% patients in no IABP
arm crossed over to IABP arm. There was no difference in the
primary end point of mortality among the various subgroups
of age, gender, type of MI and blood pressure.
Major limitations in this study as discussed in the accom-
panying editorial were a relatively smaller sample size and
a lower mortality rate as compared with other contemporary
trials. This makes it a relatively moderate risk group where
benefit of IABP may be lower than in high risk patients. A 10%
crossover rate is another limiting factor, although on treat-
ment analysis after accounting for the crossover, also failed to
prove benefit for IABP use.
Perspective
Fifty years after first technical demonstration of the utility of
IABP at the Cleveland clinic, several serious questions are
being raised regarding the efficacy of IABP. Although IABP is
a class I recommendation for refractory cardiogenic shock as
per ACC/AHA and ESC guidelines, the evidence for the use of
IABP ismainly from small randomised studies or retrospective
analysis. The basic haemodynamic principle of IABP is
improvement in diastolic coronary perfusion and systolic
unloading of the heart. Intuitively this principle appears quiet
promising in the setting of STEMI with cardiogenic shock but
has failed on clinical grounds. A meta-analysis published in
2009 also failed to show any benefit for IABP in the setting of
primary PCI with cardiogenic shock.
Twomore trials published recently have failed to show any
benefit for IABP in the setting of anterior wall STEMI and
complex PCI. Counter-pulsation to Reduce Infarct Size Pre-
PCI-Acute Myocardial Infarction (CRISP-AMI) trial rando-
mised 337 patients with stable AWSTEMI who underwent
primary PCI with/without IABP support. There was no differ-
ence in the 30-day and 6 months death or MI rates between
the two groups. Assessment of infarct size by cardiac MRI 4
days after MI was also not different. Second trial, Balloon-
Pump Assisted Coronary Intervention Study (BCIS)-1 rando-
mised patientswith low EF and undergoing PCI, to IABP and no
IABP. It had shown no difference in the risk of major adverse
cardiac and cerebrovascular events (MACCE) at the time of
hospital discharge among patients treated with IABP when
compared with those who did not receive counter-pulsation.
However, long term results of this study after a median follow
up of 51 months have shown a 34% reduction in themortality.
The three trials mentioned earlier have studied the utility
of IABP in complex PCI, STEMI and cardiogenic shock, with
none of them supporting the use of IABP in these conditions.
Registry data from Cath-PCI registry has shown no difference
